“I have been working with the team at MVT since Q4 2021 and it has been my privilege to work with Dr. Unger, Dr. Meuillet and the rest of the team. Dr. Unger, a pioneer of ultrasonic contrast media, is a great entrepreneur, inventor and innovator. Dr. Meuillet is an excellent scientist and developer. With their leadership and MVT’s strong pipeline, MVT will address unmet care needs in cardiology, vascular thrombosis, oncology and Alzheimer’s disease. We at MVT believe that our mission is to extend the time of life and enhance the quality of life,” said Mr. Lim.
David has extensive experience in financial markets, both public and private, and in the asset management industry. He co-founded Washington Square Capital, which focuses on private company acquisitions. Previously, he worked as a trader for a subsidiary of Royal Bank of Canada, with $40 billion in assets under management by the time David left the firm. His experience also includes being a proprietary trader. As a trader, David researched and developed investments to implement for the firm’s portfolios and funds while mitigating risk. In addition to his financial experience, David has advised on New York City commercial real estate transactions. He has played a vital role in the due diligence process for several investments. He is currently a consultant for a Web 3 company Plato. David received a Bachelor of Science from Rutgers University and an MBA from NYU Stern School of Business.
Emmanuelle Meuillet, PhD, Chief Scientific Officer of MVT said: “We are very excited to have David join the team as our Chief Financial Officer. David has a good relationship with the investment community.”
Microvascular Therapeutics is a privately held clinical stage biotechnology company developing ultrasound contrast agents and theranostic. MVT has multiple products in the pipeline for important unmet needs in cardiovascular disease, oncology and neurology. MVT is also in clinical development for a new, improved ultrasound contrast agent.
Microvascular Therapeutics was founded by Dr. Evan C. Unger, is an entrepreneur and pioneer in the development of Perflutren-based microbubbles. His first company, ImaRx Pharmaceutical, developed Definity®, a Perfluten microbubble that is now the world’s most sold ultrasound contrast agent for echocardiography (heart) imaging. The company has a strong portfolio of intellectual property: 11 patent families and 9 issued US patents.
For more information, contact: Emmanuelle Meuillet, [email protected]
Disclaimer: Content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Certain statements in this press release may be “forward-looking statements.” Actual events or results may differ materially due to risks and uncertainties we face. The forward-looking statements are based on current expectations as of the date of these statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information or otherwise.